Bulk RNA-seq of H1975 cells treated with Almonertinib, EGF and EGFR-knockdown

Through comprehensive genetic and pharmacological analyses across various models, we have identified glutamine fructose-6-phosphate transaminase 2 (GFPT2) as a key facilitator of immune evasion in EGFR-mutated NSCLC. Mechanistically, under EGFR mutation condition, GFPT2 expression, which is typically low in normal tissues, is highly induced via EGFR/IRE1α/Xbp1s signaling axis, leading to a significant increase in intracellular UDP-GlcNAc and consequently, an altered N-glycosylation profile. In this experiment, we analyzed H1975 cells treated with Almonertinib, EGF and EGFR-knockdown on Illumina Novaseq 6000 platform to investigate the differential gene expression.